

Special Issue

Advances in Cancer Photomedicine

Message from the Guest Editors

The current standards of care for cancer treatment in general include surgery, radiotherapy, chemotherapy, and immunotherapies. However, these modalities are not sufficient to curb the grim cancer statistics summarized above. Cancer photomedicine, with photodynamic therapy of cancer (PDT) and photochemical internalization (PCI) as its most prominent representatives in the clinic, is currently underrated and mainly limited by the poor penetration of light into tissue. Photomedical cancer treatments are cross-disciplinary, spanning synthetic chemistry, photochemistry, photobiology, bio- and nano-engineering, chemi-/bio-luminescence, photogenerated reactive oxygen species and redox systems, and clinical research, among other disciplines. In addition, several hybrid/combinatorial treatment modalities are emerging as of late. This Special Issue aims to provide an overview of the state of the art in cancer photomedicine across disciplines and also provide an outlook into future trends and prospective clinical applications.

Guest Editors

Dr. Theodossis A. Theodossiou

Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, 379 Oslo, Norway

Dr. Mantas Grigalavicius

Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, 379 Oslo, Norway

Deadline for manuscript submissions

closed (30 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/73407

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)